SCHEMBL19098941

SCHEMBL19098941

CC(CS)OCc1c(Cl)cccc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ KMT2A Q03164 3/20 0.36
▸ TAAR1 Q96RJ0 1/20 0.35
▸ ALDH1A1 P00352 4/20 0.34
▸ HTT P42858 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ USP2 O75604 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ HIF1A Q16665 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ NR1I2 O75469 1/20 0.34
▸ ESR1 P03372 1/20 0.34
▸ NR3C1 P04150 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19099544 0.89 TAAR1 (0.45) SMN1; SMN2KMT2ATAAR1ALDH1A1HTT
SCHEMBL19055367 0.83 SMN1; SMN2 (0.41) SMN1; SMN2KMT2ATAAR1ALDH1A1HTT
SCHEMBL19055337 0.81 SMN1; SMN2 (0.42) SMN1; SMN2KMT2ATAAR1ALDH1A1HTT
SCHEMBL16708451 0.80 SMN1; SMN2 (0.44) SMN1; SMN2KMT2ATAAR1ALDH1A1HTT
SCHEMBL19099546 0.80 IDO1 (0.48) TAAR1LMNAIDO1SLC6A2SLC6A4
SCHEMBL19055368 0.80 SMN1; SMN2 (0.39) SMN1; SMN2KMT2ATAAR1ALDH1A1HTT
SCHEMBL5667835 0.77 SMN1; SMN2 (0.42) SMN1; SMN2KMT2ATAAR1ALDH1A1HTT
SCHEMBL19099315 0.73 TAAR1 (0.46) SMN1; SMN2KMT2ATAAR1ALDH1A1HTT
SCHEMBL19098853 0.71 SMN1; SMN2 (0.38) SMN1; SMN2KMT2ATAAR1ALDH1A1HTT
SCHEMBL6637109 0.71 AKR1B1 (0.43) SMN1; SMN2KMT2ATAAR1ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10189777-B2 Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease LYCERA CORPORATION (US) 2019-01-29 — — US disclosed
US-20170190659-A1 BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE WILMINGTON TRUST, NATIONAL ASSOCIATION 2017-07-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10189777-B2 Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease RORC, RORB, RORA SMN1; SMN2 2811/4885KMT2A 2706/4885TAAR1 894/4885
US-20170190659-A1 BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE RORB, RORA, RORC SMN1; SMN2 3028/4885KMT2A 2458/4885TAAR1 779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback